Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Pulmonary Embolism I: Introduction01:19

Pulmonary Embolism I: Introduction

A blood clot, or thrombus, is a semi-solid mass composed of fibrin, platelets, and red blood cells. When it forms within a vessel, it can obstruct blood flow, known as thrombosis. If part of the clot detaches, it becomes an embolus that can travel and block distant vessels. When this occurs in the pulmonary arteries, it causes a condition known as pulmonary embolism (PE).Origin and ImpactMost often, the embolus originates from a thrombus in the deep veins of the lower limbs, a condition called...
Pulmonary Embolism I: Introduction01:29

Pulmonary Embolism I: Introduction

Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Is reduced right ventricular power after sotatercept beneficial?

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2026
Same author

Multi-organ metabolic connectivity mapping in advanced pulmonary arterial hypertension: a group-level 18 F-FDG PET-controlled study.

BMC medical imaging·2026
Same author

Reply: <i>FLNA</i> loss-of-function variants in pulmonary hypertension: implications for genetic testing in congenital heart disease.

The European respiratory journal·2026
Same author

Venular remodeling as an integral component of CTEPH Rather Than a Distinct Pathology.

American journal of respiratory and critical care medicine·2026
Same author

Fenfluramine-associated pulmonary hypertension: a study of adverse events reporting system FAERS.

ERJ open research·2026
Same author

Functional and Molecular Characterization of Novel <i>GDF2 (BMP9</i>) and <i>BMP10</i> Variants From the French PAH and HHT Cohorts.

Circulation. Genomic and precision medicine·2026

Related Experiment Video

Updated: Jun 13, 2026

Rodent Inferior Vena Cava Venoplasty Balloon Model
05:44

Rodent Inferior Vena Cava Venoplasty Balloon Model

Published on: May 24, 2024

Pulmonary veno-occlusive disease: recent progress and current challenges.

David Montani1, Dermot S O'Callaghan, Laurent Savale

  • 1Service de Pneumologie et Réanimation Respiratoire, Hôpital Antoine-Béclère, Assistance Publique - Hôpitaux de Paris, Université Paris-Sud 11, INSERM U999, Centre National de Référence de l'Hypertension Pulmonaire Sévère, 92140 Clamart, France.

Respiratory Medicine
|May 12, 2010
PubMed
Summary

Pulmonary veno-occlusive disease (PVOD) is a rare, serious lung condition causing high blood pressure and heart failure. Early diagnosis and lung transplantation are crucial for survival, as treatments are limited.

More Related Videos

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis
06:59

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis

Published on: August 26, 2025

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat
08:34

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat

Published on: November 18, 2018

Related Experiment Videos

Last Updated: Jun 13, 2026

Rodent Inferior Vena Cava Venoplasty Balloon Model
05:44

Rodent Inferior Vena Cava Venoplasty Balloon Model

Published on: May 24, 2024

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis
06:59

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis

Published on: August 26, 2025

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat
08:34

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat

Published on: November 18, 2018

Area of Science:

  • Cardiology
  • Pulmonology
  • Pathology

Background:

  • Pulmonary veno-occlusive disease (PVOD) is an uncommon cause of pulmonary arterial hypertension (PAH).
  • It involves progressive obstruction of small pulmonary veins, leading to elevated pulmonary vascular resistance and right ventricular failure.
  • Despite advances in PAH treatment, PVOD prognosis remains poor, with limited survival without intervention.

Purpose of the Study:

  • To summarize the key features, diagnostic challenges, and treatment options for pulmonary veno-occlusive disease.
  • To highlight the importance of integrated diagnostic approaches beyond clinical presentation alone.
  • To discuss current therapeutic strategies and the role of lung transplantation.

Main Methods:

  • Review of histopathological hallmarks, including fibrous intimal proliferation in pulmonary venules.
  • Integration of non-invasive diagnostic tests: high-resolution computed tomography, pulmonary function testing (DLCO), arterial blood gas analysis, and bronchoalveolar lavage.
  • Assessment of clinical distinctions between PVOD and PAH, noting higher male prevalence and tobacco exposure in PVOD.

Main Results:

  • PVOD diagnosis is challenging, often requiring integrated non-invasive testing due to risks associated with surgical lung biopsy.
  • Clinical presentation can mimic PAH, but specific imaging and functional test findings aid differentiation.
  • PAH-specific treatments may worsen PVOD by causing pulmonary edema, necessitating cautious management.

Conclusions:

  • Pulmonary veno-occlusive disease presents a significant diagnostic and therapeutic challenge within the spectrum of pulmonary hypertension.
  • Integrated non-invasive diagnostic strategies are essential for accurate PVOD identification.
  • Lung transplantation remains the primary curative option, while medical management requires careful consideration of potential risks.